Clinical Trial Update: Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Bet v1 antibodies for eye allergy symptoms in adolescents and adults with birch pollen allergy. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Birch Pollen Allergy

Drugs mentioned

• Bet v1 antibodies (bet v1-targeting monoclonal antibodies)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Allergic Conjunctivitis | Phase 3 | Status: RECRUITING